BioPharma Dive - Latest News

AstraZeneca quietly exits neuroscience

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core therapeutic areas” and “high value” programs.

May 1, 2025 - 17:04
 0
AstraZeneca quietly exits neuroscience

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core therapeutic areas” and “high value” programs.

Read More

Tags:

Previous Article

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

Next Article

Alliant Energy commissions solar capacity with 200MW Iowa plant

Related Posts

J&J secures FDA OK for immune drug touted as future blockbuster

J&J secures FDA OK for immune drug touted as future blo...

Apr 30, 2025  0

Pfizer’s Bourla ‘cautiously optimistic’ on looming US pharma tariffs

Pfizer’s Bourla ‘cautiously optimistic’ on looming US p...

Apr 29, 2025  0

Bristol Myers’ prized schizophrenia drug stumbles in testing

Bristol Myers’ prized schizophrenia drug stumbles in te...

Apr 23, 2025  0